Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

October 1, 2024

Conditions

Primary Hemophagocytic Lymphohistiocytosis

Trial Locations (1)

Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors

lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT06587191 - Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis | Biotech Hunter | Biotech Hunter